We may earn a commission if you buy through this link, at no extra cost to you.
Plain answer first. When people say “peptides” online, they often mix three different lanes. Mixing them causes most beginner confusion.
This page teaches the map. It does not list products to shop. It does not say which lane is right for a personal goal.
These are finished drug products that went through the drug-approval path. They have labeled indications, labeled quality standards, and regulator oversight as drugs.
RUO means research use only. On many storefronts it is paired with not for human consumption.
This hub’s RUO page explains the site framing in more detail: /ruo.
Compounding means a pharmacy (or, under 503B, an outsourcing facility) makes a custom medicine from ingredients under special U.S. drug law. Conditions matter. Compounded is still not the same as FDA-approved.
§503A covers traditional compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. It is generally tied to a prescription for an identified individual patient (with limited anticipatory compounding). If all statutory conditions are met, 503A can exempt the compounder from certain FD&C Act requirements — including CGMP §501(a)(2)(B), “adequate directions” labeling §502(f)(1), and new-drug approval §505. Bulk drug substances used under 503A must meet the statute’s bulk rules (for example USP/NF monograph + compounding chapter, or a component of an FDA-approved drug, or placement on the 503A Bulks List developed by regulation — plus related COA / manufacturer conditions). Interim Category 1/2/3 PDFs are enforcement posture while nominations are evaluated. They are not the same as the final 503A Bulks List in the Code of Federal Regulations.
Category aside: When a compound name shows up in Category-list talk, do not cite the Category PDF alone. Read the interim Category lists (https://www.fda.gov/media/94155/download) together with FDA’s Significant Safety Risks page — including the “nominated but withdrawn” table. Full dual-cite pattern, BPC/TB/KPV myth correction, and PCAC is/isn’t: /fda-compounding-status.
§503B was added by the Drug Quality and Security Act (enacted 2013-11-27, Pub. L. 113-54). It creates a voluntary outsourcing facility pathway. Compounding happens by or under the direct supervision of a licensed pharmacist in a facility registered as an outsourcing facility. 503B facilities may or may not obtain patient-specific prescriptions (for example office stock). If conditions are met, 503B can exempt from some labeling and approval requirements — but outsourcing facilities remain subject to CGMP. Bulks generally must appear on the 503B clinical-need Bulks List or the compounded drug must be on the shortage list at the relevant time (plus monograph / COA / manufacturer conditions when they apply).
Hub lock: PCAC advice does not itself put a substance on those lists. See /fda-compounding-status.
| Question | Lane 1 — Approved drug | Lane 2 — RUO | Lane 3 — Compounding |
|---|---|---|---|
| Is it an FDA-approved finished drug? | Yes (for that labeled product) | No | No — compounded ≠ approved |
| Typical label vibe | Drug labeling / indication | Research use only / not for human consumption | Pharmacy / outsourcing facility practice under 503A or 503B conditions |
| Does a COA equal approval? | N/A as “RUO proof” | No | No |
| Are influencer nicknames a pathway? | No | No | No |
(1) FDA-approved peptide drugs. (2) Gray-market RUO research chemicals labeled not for human consumption. (3) Pharmacy compounding under 503A or 503B.
It means the material is framed for research context — not as an approved medicine for people. A COA does not change that framing into drug approval.
No. Those sit in different lanes. Do not treat them as interchangeable.
503A is traditional, usually patient-specific pharmacy/physician compounding with conditional exemptions (including from CGMP if all conditions are met). 503B is the outsourcing-facility track added by DQSA in 2013; it can supply without a named patient in some cases and stays under CGMP.
No. Interim Category lists are FDA’s interim enforcement posture while nominations are evaluated. They are not finished-drug approval and not automatically the same as the final 503A Bulks List. For Category vs Significant Safety Risks (dual-cite), see /fda-compounding-status.
Related: /what-are-peptides · /ruo · /fda-compounding-status · /peptide-101